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esponsibility of InstAbstract Triptolide (TP), a major active component of Tripterygium wilfordii Hook.F. (TWHF), is used to
treat rheumatoid arthritis (RA). However, it has a narrow therapeutic window due to its serious toxicities. To
increase the therapeutic index, a new triptolide-loaded transdermal delivery system, named triptolide-loaded
liposome hydrogel patch (TP-LHP), has been developed. In this paper, we used a micro-needle array to
deliver TP-LHP to promote transdermal absorption and evaluated this treatment on the pharmacokinetics
and pharmacodynamics of TP-LHP in a rat model of collagen-induced arthritis (CIA). The pharmacokinetic
results showed that transdermal delivery of microneedle TP-LHP yielded plasma drug levels which ﬁt a one-
compartment open model. The relationship equation between plasma concentration and time was
C=303.59 (e0.064te0.287t). The results of pharmacodynamic study demonstrated that TP-LHP
treatment mitigated the degree of joint swelling and suppressed the expressions of fetal liver kinase-1,
fetal liver tyrosine kinase-4 and hypoxia-inducible factor-1α in synovium. Other indicators were also
reduced by TP-LHP, including hyperfunction of immune, interleukin-1β and interleukin-6 levels in serum.
The therapeutic mechanism of TP-LHP might be regulation of the balance between Th1 and Th2, as well as
inhibition of the expression and biological effects of vascular endothelial growth factor.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).6
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Triptolide (Fig. 1A), a major active diterpenoid triepoxide isolated
from the traditional Chinese medicine Tripterygium wilfordii Hook.F.
(TWHF), has multiple pharmacological activities including anti-
inﬂammatory, immune-suppressive, anti-tumor and anti-fertility activ-
ity1–3. It has been reported to be effective in the treatment of
inﬂammatory and autoimmune diseases, especially rheumatoid arthri-
tis (RA)4. However, the clinical uses of triptolide are largely limited
because of its severe toxicities, such as gastrointestinal, liver, cardiac,
hematopoietic system and urogenital toxicity5. In China, the incidence
of adverse reactions is over 60%, especially in the gastrointestinal
tract, e.g., nausea, vomiting, cramping, diarrhea, and duodenal ulcer6.
Transdermal delivery systems can often bypass hepatic ﬁrst pass
metabolism and reduce the incidence or severity of gastrointestinal
reactions7. Therefore, a transdermal delivery system could have
signiﬁcant advantages in the clinical use of triptolide.
The nature of human skin poses signiﬁcant impediments for
transdermal drug delivery. Human skin is mainly composed of
three parts: cuticle, epidermis and dermis layer. Cuticle, the
outermost layer of skin, is the biggest barrier to percutaneous
absorption. Although some chemical penetration enhancers have
been used for transdermal drug delivery, but macromolecular
drugs (proteins, peptides, polysaccharides) do not easily penetrate
the skin8. Microneedles can break the barrier of skin, and ﬂat tips
are better than sharp tips for enhancing skin permeability9.
Collagen-induced arthritis (CIA) in the rat is a widely studied
animal model of inﬂammatory polyarthritis with similarities to
RA, and primarily mediated by an autoimmune response10.
Because of many similarities between CIA and RA, the CIA
model is the most widely used for the study of RA11.
Interleukin-1β (IL-1β) and interleukin-6 (IL-6) are involved in the
regulation of the immune response, hematopoiesis, and inﬂamma-
tory12. Two high-afﬁnity vascular endothelial growth factor (VEGF)
receptors, fetal liver tyrosine kinase-1(Flt-1)/VEGFR-1 and fetal liver
kinase-1(Flk-1)/VEGFR-2, play important role during neovascular-
ization13. Flt-4/VEGFR-3 has a critical function in the remodeling of
the primary capillary vasculature of midgestation embryos. Later
during development, Flt-4 regulates the growth and maintenance of
the lymphatic vessels14. Hypoxia-inducible factor-1α (HIF-1α) is a
master regulator of tissue adaptive responses to hypoxia, and has a
direct regulatory effect on both survival and function in inﬂammatory
microenvironments15.
In this paper, using andrographolide (Fig. 1B) as an internal
standard (IS), we established a new method for the quantitation of
triptolide in CIA rat plasma. The aim of this study was to develop
a novel formulation of triptolide and investigate the pharmacoki-
netics and pharmacodynamics of microneedle-applied TP-LHP on
rats with CIA. The ﬁndings will help to improve the developmentFigure 1 Structures of (A) triptolide and (B) andrographolide (IS).of topical formulations of TP-LHP and to optimize the therapeutic
use of this drug.2. Experimental
2.1. Animals
Sprague-Dawley male rats (8–9 weeks) weighing 180–200 g were
purchased from the Laboratory Animal Center of the Fourth Military
Medical University (Shanxi, China). The animal experiments were
approved by the Institutional Animal Ethics Committee.
2.2. Chemicals and reagents
Triptolide and andrographolide were purchased from the National
Institute for the Control of Pharmaceutical and Biological Products
(Beijing, China). Bovine type II collagen and incomplete Freund’s
adjuvant were bought from Chondrex, inc. (Redmond, WA, USA).
Interleukin-1β and interleukin-6 ELISA test kits were obtained
from eBiosciences Company (Vienna, Austria). Flk-1, Flt-4
and HIF-1α antibody were purchased from Thermo Scientiﬁc
(Fremont, CA, USA). HPLC grade methanol was obtained from
Sigma-Aldrich (Shanghai) Trading Co., Ltd. (Shanghai, China).
Deionized water was puriﬁed with a Milli-Q system (Millipore,
Milford, MA, USA). Other chemicals were of analytical grade.
2.3. Preparation of CIA model and evaluation of arthritis
The collagen II (CII) was mixed with an equal volume of incomplete
Freund’s adjuvant and emulsiﬁed. The emulsion was checked by the
non-dispersability of a drop of the emulsion in water. Rats were
injected subcutaneously at the root of the tail with 0.2 mL of the CII
emulsion. A booster immunization with 0.1 mL of the CII emulsion
was performed in the same manner after a week. Starting from the
second week after immunization, the degree of arthritis was measured
by Plethysmometer (paw volume) every week (Fig. 2). The formula
was P¼ (VV0)/V0 100%, where P represents degree of joint
swelling, V represents the volume after inﬂammation and V0
represents the volume before inﬂammation.
2.4. Preparation of triptolide-loaded liposome hydrogel patch
Liposomes were formed by the known ﬁlm dispersion method.
Liposome size and encapsulation efﬁciency were measured to assess
this method. The polydispersity index of size distribution was
described by nanometer laser particle size and zeta potential analyzer.
The encapsulation efﬁciency was measured by HPLC, and calculated
by the formula P¼ (WW1)/W 100%, where P represents encap-
sulation efﬁciency, W represents the total content of triptolide in
liposomes, and W1 represents the content of free triptolide. Egg
lecithin (450.0 mg), cholesterol (90.0 mg), and triptolide (20.0 mg)
were dissolved in ethanol (50 mL), and the solution was poured into a
250 mL round-bottomed ﬂask. Then solvent was evaporated to
dryness on a rotary evaporator under reduced pressure and lipid ﬁlm
thereby obtained was then dispersed in water (50 mL). The liposome
preparation was ﬁltered with a membrane ﬁlter (0.22 μm pore size)
and used. The average of liposome size was 201.52718.43 nm with
an encapsulation efﬁciency of 83.6271.97%.
Viscomate NP-700 (5.60 g), glycine aluminum (0.35 g), poly-
vinylpyrrolidone K-90 (4.20 g), and triptolide liposome (22.4 mL)
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(0.49 g) was dissolved in distilled water (80 mL) as phase B. Phase
B was then added to phase A and mixed by stirring slowly. The
liposomes still maintain the original structure after mixed in
glycerin with phase B revealed by transmission electron micro-
scopy. The ointment was coated onto woven fabrics. The last step
was ﬁlm mulching after gelation, and TP-LHP was prepared.
2.5. Instrument and analytical conditions
The liquid chromatographic system consisted of two LC-20AT
pumps, a Shimadzu 10ATvp auto sampler, a CTO-10Avp column
oven, a SPD-20A detector and a CBM-10Avp Plus chromatographicFigure 2 Comparison of rats (A) be
Figure 3 HPLC chromatograms of (A) triptolide, (B) andrographolid
andrographolide.station (Shimadzu, Kyoto, Japan). Analyses were performed on a
Shim-pack VP-DOS C18 analytical column (250 mm 4.6 mm i.d.,
particle size 5 μm, Shimadzu, Kyoto, Japan), which was protected by
a ODS guard column (Security Guard, Phenomenexs, USA) at
30 1C. The mobile phase was composed of methanol/water (45:55,
v/v) at a ﬂow rate of 0.50 mL/min. The detection wavelength was set
at 218 nm. Under these conditions, triptolide eluted at approximately
15 min and the internal standard at 25 min (Fig. 3).
2.6. Preparation of stock solutions and quality control samples
The standard stock solution (1 mg/mL) of triptolide was obtained in
methanol. A series of standard working solutions, consisted of sevenfore and (B) after modeling CIA.
e, (C) plasma sample and (D) plasma spiked with triptolide and
Figure 4 Electron micrographs of microneedles. (A) 200 mm micro-
needles; (B) 200 mm microneedle array.
Table 1 Precision of intra- and inter-day of HPLC assay for
determining triptolide in plasma samples.
Nominal concentration
(ng/mL)
Precision (RSD, %)
Intra-day
(n¼5)
Inter-day
(n¼3)
25 6.8 7.3
100 5.7 6.4
500 4.9 5.3
Table 2 Stability of HPLC assay for determining triptolide
in plasma samples.
Nominal
concentration
(ng/mL)
RSD (%, n¼5)
Freeze–
thaw
At 4 1C,
12 h
At 20 1C,
3 weeks
25 6.2 6.9 9.2
100 4.7 7.5 8.3
500 5.6 5.8 6.5
Table 3 Extraction recovery of HPLC assay for determining
triptolide in plasma samples.
Nominal concentration (ng/mL) Extraction recoverya (%)
25 79.1478.15
100 83.0473.39
500 85.3774.26
aExtraction recovery (%)¼Concentration found/Concentration
added 100. Data are expressed as mean7SD, n¼5.
Gui Chen et al.572concentration levels (1.0, 2.5, 5, 10, 25, 50 and 100 mg/mL), were
prepared by further dilution of the standard stock solutions with
methanol. IS working solution (500 ng/mL) was prepared by diluting
IS stock solution with methanol. Working solutions were diluted with
drug-free plasma, and obtained a calibration standard range of 10–
1000 ng/mL. Samples used in quality control (25, 100 and 500 ng/mL
of triptolide in rat plasma) were prepared in the same way.2.7. Preparation of samples
The plasma (0.5 mL) was spiked with 50 μL of IS working
solution, after which it was vortex-mixed for 30 s and extracted
with ethyl acetate (1 mL) by vortex mixing for 2 min. This tube
was then centrifuged at 4000 rpm for 5 min. The upper organic
phase was transferred into a new tube and dried under nitrogen.
Subsequently, the residues were reconstituted in 150 μL methanol
and centrifuged at 14,000 rpm for 10 min after vortex mixing, and
10 μL supernatant was injected into the column for analysis.2.8. Pharmacokinetic study
Twelve CIA rats were divided into two groups randomly: group A
(i.g. administration) and group B (TP-LHP under microneedles).
After an overnight fast (withdrawing food but not water), group A
was given a single dose (0.40 mg/kg) of triptolide formulated in 20%
propylene glycol aqueous solution (v/v). Group B was pierced by
200 mm microneedle array (5 N force, 1 min) which was linked to a
thrust meter and then pasted TP-LHP with 1.6 mg/kg triptolide.
Fig. 4A and B showed the electron micrographs of 200 mm
microneedles and 200 mm microneedle arrays. About 0.5 mL of
blood samples were collected from the retro-orbital venous plexus
with heparinized capillary tubes before (0 h) and at 0.083, 0.25, 0.5,
1, 1.5, 2, 4, 6, 8, 10 and 12 h after dosing in group A, while we
collected the blood samples before (0 h) and 0.5, 1, 2, 4, 6, 8, 10, 12,
16, 20, 24 and 28 h after dosing in group B. Plasma was separated by
centrifugation at 8000 rpm for 10 min.2.9. Pharmacodynamic study
Nine normal rats were randomly selected as normal group, and 36
rats with CIA were divided into four groups, which are CIA group,
TP-LHP low dose group, TP-LHP middle dose group, and
TP-LHP high dose group. Two weeks after successfully modeling
CIA, normal and model groups were given 200 μm, micro-electro-
mechanical system (MEMS) micro-needle array to deal with
bilateral hind (at the force of 5 N for 1 min), and then paste the
blank TP-LHP. Three TP-LHP treated groups were given the same
treatment with 200 μm micro-needle array. The doses of triptolide
were 10 mg/kg, 20 mg/kg, and 40 mg/kg, respectively. Medication
was administered continuously for four weeks.2.10. ELISA assay
Blood samples were taken via the groin artery of rats under ether
anesthesia and the serum was obtained by centrifugation at
2500 rpm for 20 min. IL-1β and IL-6 levels in serum were
determined by ELISA test kits.2.11. Immunohistochemistry assay
The expressions of Flk-1, FLT-4 and HIF-1α in synovium were
detected by immunohistochemistry assay. Positive expression
averages of 9 samples (3 scoops in each sample) in each group
were determined by Leica-Qwin Image Analysis (Leica Micro-
systems, Germany). The percentage of positive expression in the
whole screened area was calculated.
Figure 5 Mean plasma concentration–time proﬁle of triptolide (n¼6). (A) After i.g. administration at a single dose of 0.4 mg/kg triptolide
solution; (B) After transdermal delivery of TP-LHP with 1.6 mg/kg of triptolide under microneedles.
Table 4 Pharmacokinetic parameters of triptolide by i.g.
administration and transdermal delivery under microneedles.
Parameter Unit Administration method
i.g. Transdermal
t1/2 (K) h 0.59570.321 10.83173.414
t1/2 (Ka) h 0.49770.115 2.41070.896
t1/2β h 2.58470.766 20.85375.729
Tmax h 0.98270.282 6.59271.591
Cmax ng/mL 182.46747.691 153.32726.463
AUC0-1 ng.h/mL 773.63768.34 4038.457527.74
Data are expressed as mean7SD, n¼5.
Figure 6 Changes on degree of joint swelling in CIA and TP-LHP
treated groups. *Po0.01, **Po0.01, ***Po0.001 vs. CIA group, n¼9.
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All data were expressed in mean7standard deviation (SD) and
analyzed via SPSS 18.0 software. Statistical signiﬁcance was
determined using repeated-measures ANOVA, one-way ANOVA
and LSD-t test, with P-values o0.05 regarded as statistically
signiﬁcant.3. Results
3.1. Method validation
3.1.1. Linearity
Calibration curves are plotted as the peak area ratio (triptolide/IS)
versus triptolide concentrations. The calibration curves show
good linearity (R2¼0.9991) over the concentration range of
10–1000 ng/mL. The best ﬁt linear regression equation is
y¼0.1069 xþ0.0057, where x represents triptolide concentration
in ng/mL and y represents triptolide area/IS area.
3.1.2. Precision
Table 1 displays the precision of the HPLC method for
determining of triptolide in plasma samples. The intra-day preci-
sion (RSD) ranged 4.9%–6.8% and the inter-day precision ranged
5.3%–7.3%. Thus, the method has a satisfactory precision and
reproducibility.
3.1.3. Stability
Table 2 shows the stability of triptolide under following condi-
tions: (1) three freeze–thaw cycles, (2) 4 1C for 12 h, (3) 20 1C
for 3 weeks. As a result, triptolide showed good stability at the
three conditions.
3.1.4. Recovery
The extraction recovery of triptolide was above 80% on average
(Table 3), and the dependence on concentration was negligible.
The recovery of IS was 75.26% at the concentration used in the
assay (500 ng/mL).
3.2. Pharmacokinetic study
The HPLC method was successfully used for the pharmacokinetic
study following i.g. administration at a single dose of 0.4 mg/kg
triptolide solution and transdermal delivery of TP-LHP under
micro-needle. The mean plasma concentration–time proﬁles for
triptolide are shown in Fig. 5. The pharmacokinetic parameters of
triptolide were calculated by Drug and Statistics (DAS) software.
The main pharmacokinetic parameters are shown in Table 4.
Transdermal delivery of micro-needle TP-LHP yielded plasma
Figure 7 The organ coefﬁcients of (A) heart, thymus, and spleen and (B) adrenal. *Po0.05 vs. control group; #Po0.05, ##Po0.01 vs. CIA
group, n¼9. There was no signiﬁcant difference in the organ coefﬁcients of spleen and adrenal in each group.
Gui Chen et al.574drug proﬁles which ﬁt the one-compartment open model. The
relationship equation between plasma concentration and time was
C¼303.59 (e0.064te0.287t).3.3. Degree of joint swelling
Fig. 6 shows the changes in joint swelling in the CIA and TP-LHP
groups. The degree of joint swelling in TP-LHP high dose group
was signiﬁcantly decreased from the ﬁrst week after treatment (vs.
CIA group, *Po0.05). Both middle and high dose of TP-LHP
obviously decreased the degree of joint swelling from the second
week to the third week (*Po0.05), and the difference was more
pronounced at the fourth week (**Po0.01, ***Po0.001).Figure 8 Changes on IL-1β and IL-6 level in serum. *Po0.05,
**Po0.001 vs. normal group; #Po0.05, ##Po0.01, ###Po0.01 vs
CIA group; n¼9.3.4. Organ coefﬁcient
Fig. 7 shows the organ coefﬁcients of heart, thymus, adrenal and
spleen. There was no signiﬁcant difference in the organ coefﬁ-
cients of adrenal and spleen in each group. Higher organ
coefﬁcient of heart was found in the rats of CIA group
(*Po0.05 vs. normal group), while TP-LHP at all dose levels
could reverse this change (#Po0.05, ##Po0.01 vs. CIA group).
However, TP-LHP at middle dose had more signiﬁcant difference.
Attention should be paid to this, as the organ coefﬁcient of heart
could increase with the dose.3.5. IL-1β and IL-6 level in serum
Fig. 8 shows the IL-1β and IL-6 level in serum. Higher levels of
IL-1β were found in serum of CIA group and low-dose TP-LHP
treated group (*Po0.05 vs. normal group), while lower levels of
IL-1β were observed in serum of middle-dose and high-dose TP-
LHP treated groups (#Po0.05, ###Po0.001 vs. CIA group). The
rats in CIA group showed higher serum level of IL-6 (***Po0.001
vs. normal group). TP-LHP at all dose levels could reverse the
change of IL-6 (##Po0.01, ###Po0.001 vs. CIA group).3.6. Changes on Flk-1, Flt-4 and HIF-1α expression in
synovium
Fig. 9 A–F shows the expressions of Flk-1, Flt-4, and HIF-1α in
synovium, whereas Fig. 9G shows the percentage of the
positive expression in synovium. Higher expression levels of
Flk-1 were found in CIA, TP-LHP low dose and middle
dose group (Po0.001, vs. normal group) and TP-LHP
at high dose level could reverse this change (Po0.001,
vs. CIA group). Although the expression of Flk-1 in
TP-LHP low-dose group also decreased, the difference was not
signiﬁcant.
Higher expression levels of Flt-4 were found in the CIA group
(Po0.001, vs. normal group), while TP-LHP at middle and high
dose levels could reverse this change (Po0.001, vs. CIA group).
Although the expression of Flt-4 in TP-LHP low-dose group also
decreased, the difference was not signiﬁcant.
Figure 9 The expressions of Flk-1, Flt-4, and HIF-1α in synovium. (A) Flk-1 in normal group; (B) Flk-1 in CIA group; (C) Flt-4 in normal
group; (D) Flt-4 in CIA group; (E) HIF-1α in normal group; (F) HIF-1α in CIA group. The brown–yellow stains were deﬁned as the positive
expressions. (G) The percentage of the positive expression of Flk-1, Flt-4 and HIF-1α in synovium. *Po0.05, **Po0.01, ***Po0.001 vs. normal
group; #Po0.05, ##Po0.01, ###Po0.001 vs. CIA group; n¼9.
Figure 10 Histological section of rat skin pierced by 200 µm
microneedles.
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LHP low dose group (**Po0.01, ***Po0.001, vs. normal group),
while TP-LHP at middle and high dose levels could reverse this
change (#Po0.05, ##Po0.01, vs. CIA group).4. Discussion
The present ﬁndings conﬁrmed that microneedles can pierce the skin
and form conduits (Fig. 10) which enhance transdermal drug delivery.
Compared with i.g. administration, TP-LHP had a slower time-
to-peak and longer stability of plasma concentration. There was a
signiﬁcant increase in the AUC0-1, which indicated that TP-LHP
improved the bioavailability of triptolide.
The degree of joint swelling was mitigated by TP-LHP at all
dose levels. There was a signiﬁcant change after one week’s
treatment in TP-LHP high dose group. Drug administration over
2–3 weeks achieved a smooth period in which the degree of joint
swelling had no obvious changes. After four weeks’ treatment,
joint swelling was further mitigated. The mechanism for these
effects may be that triptolide inhibited formation and release of
inﬂammatory mediators.
There were no signiﬁcant differences between spleen coefﬁcient
and adrenal coefﬁcient in each group, while the thymus coefﬁ-
cients in CIA group and TP-LHP low-dose group were signiﬁ-
cantly higher than normal group. The CIA model induced by
collagen II, an immune hyperthyroidism model, produced arthritis
symptoms which were signiﬁcantly mitigated by high doses of
TP-LHP.
Gui Chen et al.576The heart coefﬁcient in CIA group was signiﬁcantly higher
than normal group. The reason might be that RA increased
cardiac load. TP-LHP at low dose had no signiﬁcant effect on
heart coefﬁcient of CIA model, while TP-LHP at middle and high
doses produced signiﬁcant reductions. These results showed that
TP-LHP at certain doses can improve RA and reduce heart
damage. However, the heart coefﬁcient increased with the
increased doses, suggesting that overdose of TP-LHP might
cause heart damage.
Signiﬁcant effects on IL-1β levels were found in the middle and
high-dose TP-LHP groups, and IL-6 levels were remarkably reduced
by TP-LHP at all doses. This indicates that therapeutic action of
TP-LHP might relate to the regulation of Th1/Th2 balance.
The results of immunohistochemistry assays indicated that TP-
LHP produced dose-related inhibition of the expression of Flk-1,
Flt-4 and HIF-1α. TP inhibited the expression of Flk-1 and Flt-4
which are VEGF receptors. Thus TP-LHP inhibited the biological
effects of VEGF mediated by Flk-1 and Flt-4. Inhibiting the
expression of HIF-1α, TP declined the expression of VEGF
induced by HIF-1α. Therefore, suppressing the expression and
biological effects of VEGF is an important mechanism for the
therapeutic effects of TP-LHP.5. Conclusions
Microneedle technology can be used in topical formulations for
enhancement of drug delivery. When triptolide was prepared as
TP-LHP, the hepatic ﬁrst-pass metabolism and digestive toxicity
were eliminated. TP-LHP provided stable, long-term release of
triptolide, and had signiﬁcant efﬁcacy in the CIA model. The
combination of TP-LHP and microneedle technology could
provide a safe and efﬁcient administration method of triptolide
for treating RA.Acknowledgment
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